Trial · NCT06454968
Orelabrutinib Combined With Obinutuzumab and Lenalidomide (OGL Regimen) as First-line Treatment for Marginal Zone Lymphoma.
NCT06454968, Phase 2, Recruiting, Peking Union Medical College Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Orelabrutinib Combined With Obinutuzumab and Lenalidomide (OGL Regimen) as First-line Treatment for Marginal Zone Lymphoma. Trials, record NCT06454968. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06454968
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Orelabrutinib Combined With Obinutuzumab and Lenalidomide (OGL Regimen) as First-line Treatment for Marginal Zone Lymphoma.
- NCT number
- NCT06454968
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 45 participants, estimated
- Lead sponsor
- Peking Union Medical College Hospital
- Conditions
- Marginal Zone Lymphoma
- Interventions
- Orelabrutinib, obinutuzumab, lenalidomide
- First posted
- 2024-06-12
- Last updated
- 2024-06-18
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | the best complete response rate | At the end of cycle 12(the first 6 cycles are 21 days each, and the following 6 cycles are 28 days each) | CRR is defined as the proportion of patients with a best response of CR |
| Secondary | ORR | At the end of therapy(up to 42 weeks) | ORR is defined as the proportion of patients with a response of CR or PR |
| Secondary | CRR | At the end of therapy(up to 42 weeks) | CRR is defined as the proportion of patients with a best response of CR |
| Secondary | The best ORR | At the end of cycle 12(the first 6 cycles are 21 days each, and the following 6 cycles are 28 days each) | The best ORR is defined as the proportion of patients with a best response of CR or PR |
| Secondary | 2 years progression-free survival Progression free survival (PFS) | From date of signing the informed consent until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years] | PFS is defined as the time from registration to the first occurrence of progression or relapse as assessed by the investigator, or death from any cause. PFS for patients without disease progression, relapse, or death will be censored at the time of the last tumor assessment. |
| Secondary | 2 years overall survival | From date of signing the informed consent until the date of death from any cause, whichever came first, assessed up to 2 years] | Overall survival is defined as the period from the induction registration to death from any cause. Patients who have not died until the time of the analysis will be censored at their last contact date. |
| Secondary | TTR | Up to 2 years | TTR is defined as the time from registration to the first response. |
| Secondary | Duration of Response (DOR) | Up to 2 years | Duration of response as defined as the period from the first response (at least PR) to treatment until evidence of disease progression, relapse or death of any cause. Patients alive without progression and relapse will be censored at the latest tumor assessment date or the stopping date. |
| Secondary | The occurrence of adverse events and serious adverse events | One month after the end of treatment（up to 46 weeks） | Adverse events will be graded by the investigator according to the NCI-CTCAE Version 5.0. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 40550489 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06454968
GET https://conductscience.org/api/trials/v1/NCT06454968/registered